LOS
ANGELES, April 14, 2023 /PRNewswire/ -- ImaginAb
Inc., a global biotechnology company developing 89Zr crefmirlimab
berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical
therapies (RPT) announces a poster presentation at AACR 2023 (#
3577 / 2 Poster PET, MRI, and CT Imaging April 18, 2023) of an independent analysis
undertaken by AstraZeneca (LSE/STO/Nasdaq: AZN), on data from
ImaginAb's IAB-CD8-201 'iCorrelate' Phase II study. The analysis
shows baseline and early on-treatment CD8 ImmunoPET/CT may be able
to distinguish responders from non-responders in patients receiving
standard of care immune checkpoint blockade (ICB) therapy. The
poster analysis notes:
- Adopting a lesion scoring system based on measurements from CD8
ImmunoPET/CT stratification is achieved at a median of 35 days,
providing response evaluation at a much earlier time point than
RECIST where the median best is 105 days.
- Complementarity of CD8 ImmunoPET and CT measurements, as shown
by the substantial reduction in discriminative power between the
two cohorts when restricting the lesion scoring system to either
the CD8 ImmunoPET uptake or CT measurements alone.
Ian Wilson, Chief Executive
Officer of ImaginAb, said:
"These results of the independent data analysis highlight the
potential for CD8 ImmunoPET/CT to be used as a robust decision
maker in investigational immunotherapy trials for early assessment
of pharmacodynamic response, which may help establish drug
mechanism of action, prioritization of indications/tumor types,
dose optimization and escalation, and to evaluate efficacy of mono
vs combination therapies."
|
|
Potdevin,
G
|
A first assessment of
CD8-PET/CT with 89-Zr-Crefmirlimab as predictive biomarker for
response to standard of care immunotherapy in patients with solid
tumors.
|
Abstract #
3577/2
Poster
PET, MRI, and CT
Imaging
18 April
2023
|
About ImaginAb
A clinical stage, revenue-generating global biotechnology
company developing next-generation imaging agents and
radiopharmaceutical therapy products through its proprietary
minibody and cys-diabody platforms. The lead candidate, CD8
ImmunoPET™, is currently in Phase II clinical trials and has been
licensed by pharmaceutical and biotech companies for use in
immunotherapy clinical trials.
About CD8 ImmunoPET™
An 89Zr-labelled minibody designed to bind to the CD8 receptor
on human T cells for quantitative, non-invasive PET imaging. This
method is currently being researched to determine whether it may be
used to diagnose the immune status of a patient, to measure the
efficacy of immunotherapies and predict patient outcomes.
More information:
https://imaginab.com/products/cd8-immunopet/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-analysis-of-phase-ii-data-at-aacr-assesses-imaginabs-investigational-cd8-immunopet-technologys-ability-to-predict-response-in-immunotherapy-301797289.html
SOURCE ImaginAb, Inc.